Aurinia Pharmaceuticals Inc. Q1 FY26 Results

Summary

Aurinia Pharmaceuticals Inc. reported financial results for the three months ended March 31, 2026. Total revenue was $77.7 million, up 24% from $62.5 million in the same period of 2025. Net income increased by 48% to $34.4 million, and diluted earnings per share rose by 56% to $0.25. The company reiterates its 2026 total revenue guidance of $315 million to $325 million, representing an 11% to 15% increase compared to 2025.

Key Highlights

1. 1

   Total revenue for the three months ended March 31, 2026, was $77.7 million, an increase of 24% compared to $62.5 million in the same period of 2025.

2. 2

   Net product sales of LUPKYNIS for the three months ended March 31, 2026, were $73.6 million, up 23% from $60.0 million in the same period of 2025.

3. 3

   License, collaboration and royalty revenue for the three months ended March 31, 2026, was $4.1 million, a 64% increase from $2.5 million in the same period of 2025.

4. 4

   Net income for the three months ended March 31, 2026, was $34.4 million, up 48% from $23.3 million in the same period of 2025.

5. 5

   Diluted earnings per share for the three months ended March 31, 2026, was $0.25, a 56% increase from $0.16 in the same period of 2025.

6. 6

   Cash flows from operating activities for the three months ended March 31, 2026, were $32.6 million, up 2408% from $1.3 million in the same period of 2025.

7. 7

   Aurinia reiterates its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025.